Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient

Acquired hemophilia is a rare, life-threatening coagulopathy in adults caused by the development of autoantibodies against factor VIII. Bypass agents such as recombinant factor VIIa (rFVIIa) are usually preferred for bleeding control; however, thromboembolic complications may occur. We report here a...

Full description

Saved in:
Bibliographic Details
Published inBlood coagulation & fibrinolysis Vol. 23; no. 1; p. 69
Main Authors Katgi, Abdullah, Ataca, Pinar, Kahraman, Selda, Pişkin, Ozden, Ozcan, Mehmet A, Demirkan, Fatih, Ozsan, Güner H, Undar, Bülent
Format Journal Article
LanguageEnglish
Published England 01.01.2012
Subjects
Aged
Brain Ischemia - chemically induced
Factor VIIa - adverse effects
Factor VIIa - therapeutic use
Hemophilia A - drug therapy
Humans
Male
Meta-Analysis as Topic
Recombinant Proteins - adverse effects
Recombinant Proteins - therapeutic use
Stroke - chemically induced
Online AccessGet more information

Cover

More Information
Summary:Acquired hemophilia is a rare, life-threatening coagulopathy in adults caused by the development of autoantibodies against factor VIII. Bypass agents such as recombinant factor VIIa (rFVIIa) are usually preferred for bleeding control; however, thromboembolic complications may occur. We report here a case that presented with extensive cutaneous and mucosal bleedings due to factor VIII inhibitors and was treated successfully with rFVIIa and steroid therapy, but was complicated with a life-threatening thromboembolic attack during follow-up.
ISSN:1473-5733
DOI:10.1097/MBC.0b013e32834b8267